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Background: Anlotinib is a novel multi-target tyrosine kinase inhibitor that is designed to primarily inhibit
VEGFR2/3, FGFR1-4, PDGFR α/β, c-Kit, and Ret. We aimed to evaluate the safety, pharmacokinetics, and antitumor
activity of anlotinib in patients with advanced refractory solid tumors.
Methods: Anlotinib (5–16 mg) was orally administered in patients with solid tumor once a day on two
schedules: (1) four consecutive weeks (4/0) or (2) 2-week on/1-week off (2/1). Pharmacokinetic sampling was
performed in all patients. Twenty-one patients were further enrolled in an expanded cohort study on the
recommended dose and schedule. Preliminary tumor response was also assessed.
Results: On the 4/0 schedule, dose-limiting toxicity (DLT) was grade 3 hypertension at 10 mg. On the 2/1 schedule,
DLT was grade 3 hypertension and grade 3 fatigue at 16 mg. Pharmacokinetic assessment indicated that anlotinib
had long elimination half-lives and significant accumulation during multiple oral doses. The 2/1 schedule was selected,
with 12 mg once daily as the maximum tolerated dose for the expanding study. Twenty of the 21 patients (with colon
adenocarcinoma, non-small cell lung cancer, renal clear cell cancer, medullary thyroid carcinoma, and soft tissue
sarcoma) were assessable for antitumor activity of anlotinib: 3 patients had partial response, 14 patients had stable
disease including 12 tumor burden shrinkage, and 3 had disease progression. The main serious adverse effects were
hypertension, triglyceride elevation, hand-foot skin reaction, and lipase elevation.
Conclusions: At the dose of 12 mg once daily at the 2/1 schedule, anlotinib displayed manageable toxicity, long
circulation, and broad-spectrum antitumor potential, justifying the conduct of further studies.
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Several molecular pathways play crucial roles in cancer
development, including proliferation pathways, cell-cycle
control pathways, and the processes of angiogenesis [1, 2],
where some important mediators have been success-
fully identified as potential targets for new anticancer* Correspondence: dryihebalichi@126.com; chli@simm.ac.cn
†Equal contributors
1Department of Medical Oncology, Cancer Hospital, Chinese Academy of
Medical Sciences and PUMC, Beijing 100021, China
2The State Key Laboratory of Drug Research, Shanghai Institute of Materia
Medica, Chinese Academy of Sciences, Shanghai 201203, China
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This artic
International License (http://creativecommons
reproduction in any medium, provided you g
the Creative Commons license, and indicate if
(http://creativecommons.org/publicdomain/zetreatments. Multi-targeted tyrosine kinase inhibitors (TKIs)
have demonstrated significant antitumor effects in a variety
of tumor types through the inhibition of angiogenetic and
proliferative signaling [3–5].
Anlotinib is a novel oral multi-targeted receptor tyro-
sine kinase inhibitor, which has a broad spectrum of in-
hibitory action on tumor angiogenesis and growth. The
vascular endothelial growth factor (VEGF) isoforms and
their receptors (VEGFRs) are crucial proteins in both vas-
culogenesis and angiogenesis and have been proved as ef-
fective anticancer target [3, 5, 6]. In vitro studies using
recombinant enzymes indicated that anlotinib selectivelyle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Sun et al. Journal of Hematology & Oncology  (2016) 9:105 Page 2 of 9inhibited VEGFR2/KDR and VEGFR3 approximately 20
and 500 times as potent as sunitinib and sorafenib, re-
spectively (details pending publication elsewhere). On the
other hand, dysregulation of fibroblast growth factor
(FGF)/fibroblast growth factor receptor (FGFR) axis re-
sults in aggressive cancer phenotypes by promoting cancer
progression and enhancing the angiogenic potential of
tumor microenvironment [7–9]. FGF/FGFR signaling
alterations has been connected with chemotherapy re-
sistance and poor clinical outcome [10–13]. Preclinical
results showed that anlotinib significantly inactivated
FGFR1-4, especially the FGFR2, to a greater extent than
sorafenib did.
Anlotinib suppressed tumor cell proliferation via in-
hibition of platelet-derived growth factor receptors α/β
(PDGFR α/β), c-Kit, Ret as well as Aurora-B, c-FMS, and
discoidin domain receptor 1(DDR1), which was a group of
newly identified kinase targets involving the tumor
progression [14–17]. In addition, anlotinib showed an-
titumor activity against tumor cells carrying mutations
in PDGFR α, c-Kit, Met, and epidermal growth factor
receptor (EGFR).
In vivo, anlotinib has showed broad activity against
human tumor xenograft models of the colon (SW-620),
ovarian (SK-OV-3), liver (SMMC-7721), renal (Caki-1),
glioma (U87MG), and non-small cell lung (Calu-3) during
dosing period.
In Sprague-Dawley rats and beagle dogs, anlotinib was
rapidly absorbed from the gastrointestinal tracks after
oral administration. The oral bioavailability was 23–45 %
in rats and 47–74 % in dogs. In vitro metabolism studies
demonstrated that anlotinib was primarily metabolized
by cytochrome P450-mediated hydroxylation and deal-
kylation. The oxidized metabolites were excreted directly
into the bile or excreted after conjugation mainly to
form glucuronides. Anlotinib exhibited large volume of
distribution in both species. In rats, primary tissues,
such as the lung, kidneys, liver, and heart, exhibited
significant higher exposure levels to anlotinib com-
pared with that in plasma. The exposure level in the
brain was comparable with the corresponding plasma
level. In tumor-bearing mice, anlotinib concentrated
2.4–2.6 times in tumor tissue than in plasma. Besides,
anlotinib exhibited in vitro inhibitory activities against
human cytochrome P450 3A4 and 2C9 with half max-
imum inhibitory concentrations of 0.11 and 0.25 μM,
respectively.
Based on the promising preclinical antitumor activity,
safety, and pharmacokinetics data, this phase I clinical
study was performed to determine the dose-limiting tox-
icity (DLT), maximum tolerated dose (MTD), basic
pharmacokinetics, dosage regimen recommended for
phase II trial, and preliminary antitumor effects of anlo-
tinib in patients with advanced refractory solid tumor.Methods
Eligibility criteria
Patients with pathologically and/or cytologically proven
advanced cancer with no standard therapy were included
in this study. Eligibility criteria include ages 18–65, ECOG
PS 0–1, and an estimated survival duration of more than
3 months. Patients who had used other chemotherapy
drugs need to stop for at least 30 days; patients who had
received major surgery needed to rest for at least 4 weeks.
Routine blood indices, blood lipids, liver and kidney func-
tion, and heart function (left ventricular ejection fraction)
are normal; no major organ dysfunction. Patients needed
to agree to use and utilize an adequate method of
contraception. Patients had to give written informed
consent for the study and be willing to comply with cri-
teria of follow-up.
Patients were not eligible if they had the following:
brain metastases; spinal cord compression; carcinomatous
meningitis; brain or leptomeningeal disease confirmed by
CT or MRI examination; urine protein ≥++ confirmed by
a 24-h urinary protein excretion >1.0 g; failed to heal
wounds or fractures for long term; coagulation abnormal-
ities; experienced arterial or venous thromboembolic
events before the first treatment; pre-existing thyroid dis-
ease; thyroid function could not be maintained within the
normal range under treatment; carried active hepatitis B
or hepatitis C; HIV-positive, acquired or congenital im-
munodeficiency diseases, or organ transplantation; and
serious concomitant diseases.
Study design
This was a first-in-human, phase I, open-label study of
anlotinib in advanced refractory solid tumors. The pri-
mary objective was to establish the safety profile of
anlotinib by identifying DLT, MTD, the recommended
phase II dose, and schedule. Secondary objectives included
description of single-dose and multi-dose pharmacokinetics
of oral anlotinib and assessment of preliminary antitumor
effect.
All patients provided written informed consent. The
study protocol and amendments were reviewed and ap-
proved by the Institutional Review Board, in accordance
with the Declaration of Helsinki.
Treatment
Those patients received escalating doses of anlotinib
daily for (1) four consecutive weeks (4/0) or (2) 2-week
on/1-week off (2/1). A standard 3 + 3 design was applied,
with terms for cohort expansion to six evaluable patients
if a DLT (grade 4 blood toxicity or grade 3 neutropenia
with fever ≥38.5 °C; grade 3 or higher non-hematologic
toxicity) was observed in the first cycle of treatment
among the initial three patients. If two DLTs were ob-
served during the first cycle in a cohort, dose-escalation
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MTD (the highest dose level for which the incidence of
first-cycle DLT was <33 %) was identified. In the absence
of two or more DLTs in a cohort, the dose was escalated
in a modified Fibonacci scheme. Treatment cycles were
repeated until disease progression, unacceptable toxicity,
or withdrawal of consent.
Assessment
Efficacies were evaluated according to NCI-proposed Re-
sponse Evaluation Criteria In Solid Tumors (RECIST
1.1). The tumor will be assessed every two cycles including
tumor-related symptoms and physical and imaging
examination (CT or MRI) of superficial lesions. Physical
and imaging examination of tumor lesions should be
done at least four weeks after the first effect evaluation
in patients with complete remission (CR), partial remis-
sion (PR), and stable disease (SD) to confirm efficacy.
Adverse events are graded into 0–5 according to the
National Cancer Institute Common Terminology Criteria
for Adverse Events (NCI-CTCAE 4.0). During treatment,
blood pressure will be monitored every day. Patients with
unresolved adverse reactions at the end of the test needed
to be treated and followed until the reactions returned to
the grade 1 degree or less, or stable.
Pharmacokinetic assessments
In single-dose studies, anlotinib were administered orally
at dose of 5, 10, 12, or 16 mg anlotinib/person. SerialTable 1 Patient characteristics by anlotinib dose cohort
Characteristic Number of patients
Four consecutive weeks
5 mg/person 10 mg/p
Total 4 4
Sex Male 2 2
Female 2 2
Age, year Median 39 50
Range 21–49 39–60
ECOG score 0 0 1
1 4 3
Pretreatment Surgery 3 4
Radiotherapy 2 1
Chemotherapy 4 4






ECOG Eastern Cooperative Oncology Group, MTC medullary thyroid carcinoma, CC cblood samples were collected in heparinized tubes before
and at 0.5, 1, 2, 4, 8, 11, 24, 48, 72, 96, 120, 144, 168,
192, 216, and 240 h (samples of 144–240 h were collected
only in 12 or 16 mg/person dose group) after dosing. In
the 10 mg/person dose group, urine was sampled before
and 0–2, 2–6, 6–11, 11–24, 24–34, 34–48, 48–58, 58–72,
72–96, and 96–120 h after dosing. In multiple-dose stud-
ies, there were two ways of multiple-dose administration.
Initially, patients in 5 and 10 mg/person/day groups were
treated consecutively for 28 days. Blood samples were col-
lected 24 h after dosing on days 1, 2, 4, 7, 10, 13, 15, 16,
18, 21, 24, 28, and 29. Later, the other volunteers were
given multiple doses of anlotinib at 10, 12, or 16 mg anlo-
tinib/person/day in the 2/1 schedule for two cycles. Blood
samples were collected 24 h after dosing on days 1, 4, 7,
10, 13, 15, 18, 22, 29, and 36. The collected blood samples
were centrifuged to prepare plasma fractions; the urine
samples were weighed after collection. All samples were
stored at −70 °C for subsequent analysis. Concentrations
of anlotinib were measured by liquid chromatography/
mass spectrometry.
The maximum concentration (Cmax) and the time taken
to achieve Cmax (Tmax) were obtained directly from the
data with no interpolation. The area under concentration-
time curve up to the last measured time point (AUC0 − t)
was calculated by the trapezoidal rule. The elimination
half-life (t1/2) was calculated using the relationship 0.693/
k. The k was estimated by linear regression analysis of the
terminal portion of the log concentration-time data. The2-week on/1-week off

















olorectal carcinoma, NSCLC non-small cell lung cancer, RC renal carcinoma
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mulative amount excreted into urine (Cum.Ae −U) by
plasma AUC0 − t. Accumulation ratio (Rac) was used to in-
dicate the extent of accumulation during multiple doses of
anlotinib capsules and calculated using the following
equation:
Rac ¼ C24 h Day15ð Þ=C24 h Day1ð Þ;
where C24 h(Day1) and C24 h(Day15) are plasma concentra-
tions of anlotinib at 24 h after dosing on day 1 and day
15, respectively. Plasma pharmacokinetic (PK) parame-
ters were determined using noncompartmental methodTable 2 Adverse events of patients in 12 mg/day group (the 2/1 sc
Adverse events Grade 1/2
First 2 cycles All cycles
No. of patients % No. of pat
Occurred at least one time 21 100 21
Hand-foot skin reaction 4 19 10
Rash 4 19 6
Hypertension 5 24 5
Proteinuria 5 24 14
Triglyceride elevation 6 29 11
Total cholesterol elevation 6 29 13
Hypothyroidism 8 38 12
Hyperthyroidism 2 10 2
ALT elevation 6 29 10
AST elevation 4 19 9
Creatinine elevation 1 5 2
Total bilirubin elevation 5 24 8
Lipase elevation 1 5 5
Serum amylase 4 19 9
Myocardial enzymes abnormal 2 10 3
Leukopenia 3 14 6
Neutropenia 0 0 2
Thrombocytopenia 0 0 2
Hemorrhage 0 0 1
Urine occult blood 5 24 8
Fatigue 5 24 7
Diarrhea 6 29 7
Hoarseness 3 14 5
Nausea 3 14 3
Inappetence 1 5 2
Toothache 1 5 4
Pharyngalgia 1 5 4
Premature beat 0 0 1
ALT alanine aminotransferase, AST aspartate transaminasewith a Kinetica software package (version 5.0; Thermo
Scientific, Philadelphia, PA).
Statistical analysis
The two-side test is used for all statistical tests. P ≤ 0.05
is considered as statistical significance. The measurement
data will use mean ± SD or median (min, max) for statis-
tical description. Compared with baseline data of screen-
ing period, use paired t test to compare the difference
before/after the treatment within the group. Frequency
(constituent ratio) is used for statistical description to the
enumeration data. The changes before/after the treatment
will use χ2 test (accurate probabilistic method) or non-
parametric test.hedule)
Grade 3
First 2 cycles All cycles
ients % No. of patients % No. of patients %
100 2 10 6 29
48 0 0 1 5
29 0 0 0 0
24 0 0 2 10
67 0 0 0 0
52 1 5 2 10
62 0 0 0 0
57 0 0 0 0
10 0 0 0 0
48 0 0 0 0
43 0 0 0 0
10 0 0 0 0
38 0 0 0 0
24 1 5 1 5
43 0 0 0 0
14 0 0 0 0
29 0 0 0 0
10 0 0 0 0
10 0 0 0 0
5 0 0 0 0
38 0 0 0 0
33 0 0 0 0
33 0 0 0 0
24 0 0 0 0
14 0 0 0 0
10 0 0 0 0
19 0 0 0 0
19 0 0 0 0
5 0 0 0 0
Fig. 1 The lung metastasis changes in patients of alveolar soft tissue
sarcoma with lung metastasis during treatment. a Before treatment.
b Treatment after 2 cycles (42 days). c Treatment after 3 years
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Patient characteristics
Thirty-five patients were enrolled in the study between
July 2011 and August 2013. Two cohorts of patients re-
ceived anlotinib at doses ranging from 5 mg (n = 4) to
10 mg (n = 4) once daily on the 4/0 schedule, and three
cohorts of patients at doses of 10 mg (n = 3), 12 mg (n =
21), and 16 mg (n = 3) once daily on the 2/1 schedule.
Patient baseline characteristics are presented in Table 1.
Safety and tolerability
On the 4/0 schedule, no DLT was observed in the first
four patients at the starting dose of 5 mg/day. However,
at 10 mg/day, one patient developed grade 3 hyperten-
sion among the first three patients treated. An additional
patient was enrolled and also developed grade 3 hyper-
tension. Therefore, the further dose escalation was
halted. Meanwhile, PK study revealed a continuously sig-
nificant anlotinib accumulation in patients who received
continuous administration (data not shown). Based on
the PK profile of anlotinib and the two DLTs observed at
the dose of 10 mg/day, we modified the administration
protocol from the 4/0 schedule to the 2/1.
On the 2/1 schedule, because none of the three pa-
tients experienced DLT at initial doses of 10 mg/day, the
dose escalation proceeded to 16 mg/day. Two of the three
patients in the 16 mg cohort experienced DLT (one grade
3 fatigue and one grade 3 hypertension). Therefore, the
MTD had been exceeded, and the next lower dose of
12 mg/day was further evaluated by entering additional
patients. None of the initial three patients experienced
grade 3/4 adverse events. On the basis, 12 mg once daily
was selected for the expanding study.
A total of 21 patients received the 12 mg/day dose on
the 2/1 schedule. During the first 2 cycles, all the patients
experienced an adverse event of any causality. All the
hematologic toxicities were mild. As illustrated in Table 2,
the most common non-hematologic adverse events were
hypothyroidism, triglyceride elevation, total cholesterol
elevation, ALT elevation, diarrhea, and proteinuria. During
the first 2 cycles, a total of two patients (10 %) experi-
enced grade 3 adverse events (one triglyceride elevation
and one lipase elevation). During all treatment cycles,
there were six patients (29 %) with grade 3/4 adverse
events. The most common (>5 %) non-hematologic
grade 3 adverse events were hypertension, triglyceride
elevation, hand-foot skin reaction, and lipase elevation.
Efficacy
According to the RECIST 1.1 criteria, 19 patients had
target lesions and one patient with multiple small lung
metastases had non-target lesions. Among the 20 pa-
tients whose response can be assessed, 3 patients (15 %)
had PR; 14 patients (70 %) maintained SD including 12
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(15 %) had progressive disease (PD) (Additional file 1:
Figure S1). PR was observed in the following tumor type:
two renal carcinoma and one soft tissue sarcoma. In the
current phase I study, other tumor types that responded
to anlotinib included medullary thyroid carcinoma, non-
small cell lung cancer, colorectal cancer, melanoma, thymic
carcinoma, and adenoid cystic carcinoma (Fig. 1).
The median administration duration was 24 weeks.
Twenty-four, sixteen, and nine patients had received
anlotinib for over 12, 24, and 72 weeks, respectively. Fur-
thermore, the treatment duration had exceeded 100 weeks
in three patients (Fig. 2).
Pharmacokinetics
The mean plasma level-time curve of anlotinib after a
single oral administration at 5, 10, 12, or 16 mg/subject
is shown in Fig. 3. The associated plasma PK parameters
are summarized in Table 3. Anlotinib exhibited rapid in-
testinal absorption. This was indicated by its plasma
concentration, which significantly increased at 1 h after
dosing in most patient subjects (Fig. 3). The levels of
systemic exposure to anlotinib (Cmax and AUC0–120h)
tended to increase as the dose level increased from 5 mg
anlotinib/person to 16 mg anlotinib/person, but the dose
proportionality was inconclusive (Table 3). Anlotinib
reached its maximum plasma concentration with Tmax of
4–11 h after dosing, then it eliminated slowly with t1/2
of 64–136 h and MRT of 124–167 h. The renal excre-
tion of anlotinib was poor, with a CLR of 0.004 L/h/kg;Fig. 2 Duration of treatment and tumor size changes of 20 patients who rthe fraction of the dose excreted into urine (fe −U) was
~0.9 %.
Notably, anlotinib exhibited a quite long t1/2 (96 ± 17 h),
which appeared to be dose-independent. The long t1/2
resulted in significant accumulation of plasma anlotinib
over time with a mean Rac of 12 ± 7, suggesting drug
accumulation over time (Fig. 3). The trough plasma
concentration-time curve of anlotinib after treatment
of anlotinib at 10, 12, or 16 mg/subject in the 2/1
schedule is depicted in Fig. 3. A 2-week subchronic
dosing brought about continuously increased plasma
concentration of anlotinib in patients, while its maximum
plasma concentration was reached at day 14. Subse-
quently, the plasma level of anlotinib was apparently de-
creased with a 7-day washout until the beginning of the
other treatment cycle.
Discussion and conclusions
This study evaluated the multi-targeted tyrosine kinase
inhibitor anlotinib in patients with refractory advanced
solid tumors and has met its primary objective of estab-
lishing the safety profile of anlotinib and identifying a
recommended 2/1 schedule and 12 mg-once-daily dose
for further investigation in phase II studies.
The toxicity profile of anlotinib was in agreement with
that reported in other analogous agents such as sorafenib,
sunitinib, and regorafenib [18–20]. The most frequent ser-
ious adverse events observed in this study were hand-foot
skin reaction, hypertension, fatigue, and lipase elevation.
Interestingly, some phase IV studies identified diarrhea aseceived 12 mg QD at the 2/1 schedule
Fig. 3 Plasma concentrations of anlotinib over time after a single oral dose of anlotinib capsules at 5 (green line), 10 (purple line), 12 (blue line), or
16 mg anlotinib/person (red line) in male (solid circles) and female cancer patients (open circles) (a). b Correlation of dose with plasma AUC0–120 h.
c Correlation of dose with plasma Cmax. d Correlation of dose with t1/2. e Plasma concentrations of anlotinib (24 h after daily dosing) over time
during multiple oral doses of anlotinib capsules at 12 mg anlotinib/person/day in female cancer patients. f Plasma concentrations of anlotinib
(24 h after daily dosing) over time during multiple oral doses of anlotinib capsules at 12 mg anlotinib/person/day in male cancer patients
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anti-VEGFR TKIs [18, 21, 22], but in the present study,
33 % of patients had moderate diarrhea and none devel-
oped grade 3 or 4 diarrhea, suggesting the potential of
anlotinib in decreasing gastrointestinal toxicity.
In addition, we observed high frequency of triglyceride
and cholesterol elevation in this study. Although not
resulting in uncomfortable symptoms, they still needed
regular monitor because of their close association with
arterial thromboembolic event, which was significantly
more common in patients receiving anti-VEGFR TKIs
[23]. All the adverse events appeared to be manageableeven in those patients who received anlotinib for an ex-
tended period. Our data supported the close monitor of
patients who received anlotinib in terms of lipid and
blood pressure status in the following studies.
Although efficacy was not the primary endpoint of
phase I study, the tumor response data suggested a
substantial and broad antitumor activity of anlotinib.
More than 60 % of patients who received 12 mg once
daily had tumor burden shrinkage, and the benefit
was long-lasting in several patients. Response to anlo-
tinib was noted in a wide range of tumor types, in-
cluding renal carcinoma, soft tissue sarcoma, medullary
Table 3 Pharmacokinetic parameters of anlotinib after a single oral dose of anlotinib capsules in cancer patients and summarized
results from dose proportionality assessment
Pharmacokinetic
parameters












Cmax, ng/mL 5.8 5.8 ± 2.8 10.5 ± 2.9 15.8 ± 3.2 0.629 0.003 1.12 (0.54–1.71) Inconclusive
Tmax, h 11.0 6.0 ± 4.4 7.3 ± 3.3 11.0 ± 8.9 – – – –
AUC0–120h, h·ng/mL 411 318 ± 133 617 ± 194 894 ± 305 0.465 0.045 0.81 (0.16–1.45) Inconclusive
AUC0–∞, h·ng/mL 687 562 ± 328 1066 ± 263 1585 ± 470 0.666 0.002 1.18 (0.62–1.73) Inconclusive
t1/2, h 102 95 ± 22 116 ± 47 98 ± 15 – – – –
Critical intervals were 0.791–1.209 for the systemic exposure data of anlotinib from a single oral dose of anlotinib capsules (10–16 mg) in cancer patients. The term
r denotes the correlation coefficient. Correlations were statistically significant with P < 0.05. The term “linear” was concluded statistically if the 90 % confidence interval
(90 % CI) for the slope was contained completely within the critical interval; inconclusive was concluded statistically if the 90 % CI lies partly within the critical interval;
nonlinear was concluded statistically if the 90 % CI was entirely outside the critical interval
Cmax maximum plasma concentration, Tmax the time taken to achieve the maximum plasma concentration, AUC0–120h the area under concentration-time curve up
to 120 h, AUC0–∞ area under concentration-time curve up to infinity, t1/2 terminal elimination half-life
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cancer, melanoma, thymic carcinoma, and adenoid cystic
carcinoma. This remarkable antitumor activity strongly
justified the conduct of phase II clinical trials in those
tumor types.
PK assessments in this study demonstrated that
anlotinib is rapidly absorbed through the intestine and
eliminated slowly with a half-life of 96 h, which resulted
in significantly continuous accumulation of anlotinib in
plasma over time. This is in agreement with the high
frequency of grade 3 toxicity at 10 mg in the 4/0 sched-
ule. To adapt to this PK feature, we changed the
administration protocol to the 2/1 schedule, where we
observed a 2-week subchronic rise in plasma concentra-
tion with the peak at day 14, and an apparent decline
during the 7-day washout until the beginning of next
cycle. This indicated the rational extension of administra-
tion interval is more conductive to the establishment of
optimal dose for drug with long elimination half-life
period.
Based on the toxicity and efficacy profile, anlotinib dis-
played manageable toxicity and broad-spectrum antitu-
mor potential. The recommended treatment regimen for
the following clinical studies is as follows: anlotinib
monotherapy, 12 mg per day, on the 2/1 schedule. Based
on the promising results in phase I study, a series of
phase II clinical trials have been performed and initial
efficacy has been observed in several types of solid
tumor including colon adenocarcinoma, non-small cell
lung cancer, renal clear cell cancer, medullary thyroid
carcinoma, and soft tissue sarcoma (details pending pub-
lication elsewhere).
Additional file
Additional file 1: Figure S1. Waterfall plot of best-percent change in
target lesions from baseline for the 19 patients who had target lesions on
the basis of investigator assessment. (PDF 287 kb)Abbreviations
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